

### Introduction

This special conference edition of the e-Newsletter includes the Program for the upcoming International Congress in October 2009, the members of the ISCP Executive Board, the Business Manager, Board of

Directors, Emeritus Members and the current members of the Council of Governors.

Editors: John McNeil & Lisa Demos  
e-mail: [lisa.demos@med.monash.edu.au](mailto:lisa.demos@med.monash.edu.au)

### Presidents Section


I welcome you to the 15th Congress of the International Society for Cardiovascular Pharmacotherapy. I hope you share in our mission to expand the appropriate utilization of cardiovascular drugs to prevent and treat all cardiovascular diseases to reduce the devastating cost of their morbidity and health care expenditures worldwide.

We have planned a scientific program of exciting talks by international experts that will enlighten you about the newest aspects of pharmacotherapy.

If you agree with our educational mission I hope you might join us in working with our international group of officers and members to participate in the development of new educational activities and interactive efforts with industry, academia and non-profit organizations. The

flood of new drugs, new clinical research and expanded indications for drug therapy has intensified the need for education so that these powerful tools can be used most effectively.

I hope you will find your time in Beijing both educational and pleasurable.



Jay N. Cohn, M.D.  
President

### 15<sup>th</sup> International Congress on Cardiovascular Pharmacology (ICCP)



The International Symposium will be held from 11<sup>th</sup> -12<sup>th</sup> October, 2009 in collaboration with Great Wall International Congress of Cardiology.

### Program

#### SUNDAY, OCTOBER 11, 2009

##### Drugs to Reduce Cardiovascular Risk

Co-chair: Jay N. Cohn

Co-chair: Zhu Junren

8:00 Role of endothelium in vascular and cardiac injury

**Paul Vanhoutte**

8:20 Lipid lowering drugs for primary and secondary prevention

**Rodolfo Paoletti**

8:40 Anti-hypertensive therapy: Who is at risk and what is optimal therapy?

**William Louis**

9:00 Should high-risk patients receive anti-thrombotic therapy and which one?

**Nicolas Danchin**

9:20 Modern advances in anti-smoking therapy

**John McNeil**

9:40 Neufeld Lecture

Atheromatous plaque regression

**Juan Carlos Kaski**

10:15 Break

##### Joint ISCP-GWIIC Program

Co-chair: William Louis

Co-chair: Huo Yong

10:45 CONSIDER – Survey on Cardiovascular Risk Factors in Hypertensive Patients in China

**Zhao Dong**

11:05 Management of hypertension: From hypertensive guidelines to clinical practice

**Wang Jiguang**

- 11:25 Statins: The cornerstone of anti-atherosclerosis treatment  
**Zhao Shuiping**
- 11:45 Cholesterol management recommendations for hypertensive patients  
**Zhang Weizhong**
- 12:05 Lunch

#### Neurohormonal Inhibition in Cardiovascular Therapy

Co-chair: *Dennis Cokkinos*

Co-chair: *Yan Xiaowei*

- 1:30 The renin-angiotensin system  
**Jay N. Cohn**
- 1:50 Aldosterone inhibition and cardiovascular protection: More important than it once appeared  
**Felipe Martinez**
- 2:10 Which beta blocker is most effective in heart failure?  
**Willem Remme**

#### Drug Treatment of Arrhythmias

- 2:30 Management of atrial fibrillation  
**Gheorghe-Andrei Dan**
- 2:50 Management of ventricular arrhythmias  
**Ali Oto**
- 3:10 Break

#### Management of Acute conditions: Pharmacologic Strategies and New Drugs

Co-chair: *Gheorghe-Andrei Dan*

Co-chair: *Zhu Jun*

- 3:30 Acute coronary syndromes  
**Nicolas Danchin**
- 3:50 Acute heart failure  
**Willem Remme**
- 4:10 Medical therapy of acute ST-elevation MI  
**Dennis Cokkinos**
- 4:30 Adjourn

### MONDAY, OCTOBER 12, 2009

#### Restoring Health to the Heart and Vasculature

Co-chair: *Daniel Duprez*

Co-chair: *Gao Runlin*

- 9:00 Is vascular stiffness a target for therapy?  
**Daniel Duprez**

- 9:20 Prevention and regression of myocardial remodelling  
**Dennis Cokkinos**
- 9:40 Drugs to relieve myocardial ischemia  
**Alex Battler**
- 10:00 Relative benefit of blood pressure reduction in reducing cardiovascular risk  
**William Louis**
- 10:20 Discussion
- 10:30 Break

#### Controversies in Cardiovascular Therapy I

Co-chair: *Miran Kenda*

Co-chair: *Chen Yundai*

- 11:00 Is pharmacotherapy appropriate in the elderly?  
**Miran Kenda**
- 11:20 What is the best regimen for inhibiting the renin-angiotensin system?  
**Felipe Martinez**
- 11:40 Drug therapy vs. mechanical reperfusion in chronic stable angina  
**Alex Battler**
- 12:00 Lunch

#### Controversies in Cardiovascular Therapy II

Co-chair: *Juan Carlos Kaski*

Co-chair: *Hu Dayi*

- 1:30 How to best identify candidates for pharmacoprevention  
**Jay N. Cohn**
- 1:50 Should aspirin be used for primary prevention?  
**John McNeil**
- 2:10 Is HDL still a target for therapy?  
**Rodolfo Paoletti**
- 2:30 Secondary prevention of CAD with ACE inhibitors: Struggle between life and death of the endothelium  
**Roberto Ferrari**
- 2:50 Do oral anti-diabetic drugs reduce cardiovascular disease risk?  
**Daniel Duprez**
- 3:10 Do new antianginal drugs represent a therapeutic advance?  
**Juan Carlos Kaski**
- 3:30 Critical issues in the ACC/AHA secondary prevention guidelines  
**Sidney Smith**
- 3:50 Adjourn

#### For Further Information: Secretariat of ISCP 2009

Heart Center People's Hospital, Peking University  
Room 412, Scientific Research Building, 11 Xi Zhi Men S.Ave. Beijing, 100044  
People's Republic of China  
Tel: +8610-88324726  
Fax: +8610-88381733  
Email: [iscp.09@gmail.com](mailto:iscp.09@gmail.com)  
Website: [www.gw-icc.org](http://www.gw-icc.org)

---

## Executive Board

**President:** Jay N. Cohn, USA



**Jay N. Cohn** MD is Professor of Medicine, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, and is the Director of the Rasmussen Center for Cardiovascular Disease Prevention. Prof Cohn is internationally recognized for his contributions to the understanding of therapy for cardiovascular disease and in particular heart failure.

Prof Cohn founded the Heart Failure Society of America and was the editor-in-chief of the Journal of Cardiac Failure. He is a past President of the Heart Failure Society of America, the International Society of Hypertension, and the American Society of Hypertension, as well as a past chairman of the Cardiorenal Advisory Committee of the Food and Drug Administration. Prof Cohn is also the recipient of multiple national and international awards for his research and is co-editor of the textbook *Cardiovascular Medicine*.

---

**Vice President/President Elect:** Juan Carlos Kaski, UK



**Juan Carlos Kaski** MD, DSc is Professor of Cardiovascular Science, Hon. Consultant Cardiologist, Head, Cardiovascular Biology Research Centre and Deputy Head, Division of Cardiac and Vascular Sciences, St George's, University of London.

Prof Kaski is Fellow of the Royal College of Physicians, the American College of Cardiology, the European Society of Cardiology and several other scientific societies. He is also Honorary Member of several national and international societies of Cardiology, including the British Cardiac Society and the New York Academy of Sciences. Prof. Kaski was Chairman of the Microcirculation Working Group of the European Society of Cardiology and a member of both the Training and Education Committee and the Scientific Board of the European Society of Cardiology.

---

**Past President:** Antonio Bayés de Luna, Spain




**Antonio Bayés de Luna** is Honorary Director of Service, Hospital Sant Pau, Barcelona, and Emeritus Professor in the Universidad Autónoma de Barcelona.

Prof Bayés de Luna was President of the World Heart Federation and a member of the Executive Committee of the European Board Specialists Cardiology of ESC. He has established several projects targeting cardiovascular diseases, especially in developing countries such as "The twin centres program", "The white book in world cardiology" and the yearly "World Heart Day". Prof. Bayés de Luna received "Rey Jaime I" prize on Clinical Medicine (2003), the "Creu de Sant Jordi" Medal of the Government of Catalonia (2003), the Distinguished Specific Award of the World Heart Federation (2006), and the Gold Medal of the Spanish Society of Cardiology (2007).

---

**Scientific Secretary:** John McNeil, Australia



**John McNeil** MBBS, is the Head of the School of Public Health and Preventive Medicine, Monash University, Melbourne. Prof McNeil's research interests focus on drug safety and cardiovascular disease prevention. He is a member of several Australian state based and national committees and a member of the Editorial Board of Cardiovascular Drugs and Therapeutics.

---

**Treasurer and Chairman of Nomination Committee:** Bill Louis, Australia



**Bill Louis** MD, is Professor Emeritus at the University of Melbourne. Prior to his retirement in 2007 Prof Louis was the Foundation Professor of Clinical Pharmacology & Therapeutics, at University of Melbourne and a former Director of Cardiac and Hypertension Services at Austin & Repatriation Medical Centre, Melbourne. He is a Past President and Scientific Secretary of the ISCP and his clinical and research interests are in Hypertension, Cardiovascular Risk Prevention and the development of Cardiovascular Drugs. He has played a central role in the Drug Regulatory System in Australia.

---

**Business Manager:** Marianne Burle de Figueiredo

**Marianne Burle de Figueiredo** has had a long association with societies of cardiology, heart foundations, cardiologists and persons interested in cardiac health. Marianne previously held the position of Managing Director of the World Heart Federation and the former International Society and Federation of Cardiology (ISFC). The ISCP is an Associate Member of the World Heart Federation. In 2007, Marianne accepted her position as ISCP Business Manager in an honorary capacity.

---

---

## Board of Directors

A. Battler, Israel  
G.A. Dan, Romania  
E. Escobar, Chile  
D.T. Kelly, Australia  
M. Kenda, Slovenia  
M. Maranhao, Brazil  
A. Oto, Turkey

R. Paoletti, Italy  
B.N.C. Prichard, UK  
W.J. Remme, NL  
S. Sasayama, Japan  
J. Tamargo, Spain  
P.M. Vanhoutte, Hong Kong

---

## Emeritus Members

J. Abrams, USA  
C. Kawai, Japan  
L. Opie, South Africa  
J. Papp, Hungary

E. Rapaport, USA  
W. Rutishauser, Switzerland  
ABN Singh, USA

---

## Council of Governors - June 2009

A. Capucci, Italy  
P. Clemmensen, Denmark  
D. Cokkinos, Greece  
A. Damasceno, Mozambique  
G.A. Dan, Romania  
N. Danchin, France  
D. Duprez, USA  
E. Escobar, Chile  
J.R. González-Juanatey, Spain  
N. Gotcheva, Bulgaria  
M. Hafizullah, Pakistan  
F. Hidalgo, Ecuador  
D. Hu, China  
Ch. A. Jazra, Lebanon  
M. Kenda, Slovenia  
B.M. Lombana, Panama

F. Manzur, Colombia  
F. Martinez, Argentina  
S.J. Martsevich, Russia  
A. Matsumori, Japan  
J. McNeil, Australia  
A. Oto, Turkey  
R. Pichardo, Dominican Republic  
J.A. Ramires, Brazil  
M. Rosas, Mexico  
H.P. Schultheiss, Germany  
S. Sharma, India  
G. Széplaki, Hungary  
J. Sztajzel, Switzerland  
A. Tenenbaum, Israel  
W.H. Van Gilst, Netherlands  
P.M. Vanhoutte, Hong Kong